FIP mRNA Vaccine Composition for Broad FCoV Strain Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is currently no effective treatment for Feline Infectious Peritonitis (FIP), and existing vaccines, such as the Pfizer's Primucell FIP, are not universally protective against prevalent FCoV strains, particularly type I FCoV, leading to high mortality in cats.
Innovation Solution
Development of an mRNA vaccine using Lipid Nanoparticle (LNP) carriers to deliver mRNA sequences encoding FCoV antigens, specifically the M, N, and S proteins, to induce a targeted immune response in cats, utilizing recombinant DNA elements and vectors like pUC57, pTZ19R, and expression systems to produce immunogenic proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional attenuated live vaccine (Primucell FIP) is used, then protection against type II FCoV mutant strain is achieved, but protection against prevalent type I FCoV is insufficient
Solution Approach 1:
The patent employs a multi-antigen mRNA vaccine formulation that simultaneously targets multiple FCoV strains (type I and type II) by incorporating mRNA sequences encoding antigens from different viral strains. This universal approach allows a single vaccine to provide broad-spectrum protection against diverse FCoV variants, resolving the limitation of strain-specific protection.
Solution Approach 2:
The vaccine combines multiple mRNA components encoding different FCoV antigens (S protein, N protein, M protein) into a composite formulation. This composite strategy integrates immunogenic elements from various viral strains and protein types to elicit a comprehensive immune response that covers multiple FCoV types, overcoming the narrow protection of single-antigen vaccines.
2Adaptability or versatility
If mRNA vaccine with multiple antigens is developed, then broad protection against different FCoV strains is achieved, but vaccine complexity increases
Solution Approach 1:
The patent merges multiple antigen-encoding mRNA sequences into a single integrated mRNA construct or co-delivered formulation. By combining the immunogenic benefits of S, N, and M proteins from different FCoV strains into one unified vaccine product, the approach achieves broad strain coverage while maintaining manageable formulation complexity through streamlined delivery mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mRNA vaccine effectively stimulates an immune response, potentially reducing FIP incidence and improving survival rates by inducing protective immunity against FCoV strains, including type I FCoV.
Implementation Method 1
packaging and delivery into host cells by novel Lipid Nanoparticle (LNP) carriers
Data Source
Figure 1A~2B
Figure 3A~4
Figure 5~6F
AI summary
Provided are a pharmaceutical composition for treating and preventing infectious peritonitis in animals. The pharmaceutical composition is mainly composed of M protein, N protein, and S protein which contain a FCoV virus strain, and is mainly used for preventing and treating feline infectious peritonitis. Experiments proved that the pharmaceutical composition can effectively play a role in protecting an animal body and has important significance in preventing FIP.